Dergiler / Klimik Dergisi / 2016 / Cilt: 29 - Sayı: 1

HepAtölye III: Hepatit C Virusu İnfeksiyonunun Tedavisinde Yeni Antiviraller (4-6 Aralık 2015, İstanbul)'in Ardından

After a Workshop on the Novel Antivirals for Treatment of Hepatitis C Virus Infection (4-6 December 2015, İstanbul)

Sayfa
51–54
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

AYGEN, B., ŞİMŞEK, F., AYDIN, M., TEKİN, S. (2022). HepAtölye III: Hepatit C Virusu İnfeksiyonunun Tedavisinde Yeni Antiviraller (4-6 Aralık 2015, İstanbul)'in Ardından. Klimik Dergisi, Cilt: 29 - Sayı: 1, 51–54. https://ajindex.com/articles/573596

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015, 6(1): 4-14.
  2. Vo KP, Vutien P, Akiyama MJ, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus te- laprevir or boceprevir. Dig Dis Sci. 2015; 60(4): 1045-51.
  3. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle J. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015; 62(Suppl. 1): S87-99. Türkoğlu S. Hepatit C virusu: viroloji ve seroloji. In: Tabak F, Balık İ, Tekeli E, eds. Viral Hepatit 2007. Ankara: Viral Hepatitle Sava- şım Derneği, 2007: 228-45.
  4. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368(20):1907-17.
  5. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The chan- ging landscape of hepatitis C virus therapy: focus on interferon- free treatment. Ther Adv Gastroenterol. 2015; 8(5):298-312.
  6. Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapi- es for the treatment of hepatitis C. EMBO Molecular Medicine. 2014; 6(1): 4-15.
  7. Rong L, Ribeiro RM, Perelson AS. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol. 2012; 74(8): 1789-817.
  8. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 2012; 32(Suppl. 1): 79-87.
  9. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) cir- culates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992; 66(5): 3225-9.
  10. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepa- titis C predicted by the evolution of the viral quasispecies. Sci- ence. 2000; 288(5464): 339-44.
  11. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interfer on-free combinations. Liver Int. 2014; 34(Suppl. 1): 69-78. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and tre- ating adults infected with hepatitis C virus. Hepatology. 2015; 62(3): 932-54. European Association for the Study of Liver. EASL recommen- dations on treatment of hepatitis C 2015. J Hepatol. 2015; 63(1): 199-236.